CXCR4 is highly expressed in a subset of patients with acute myeloid and lymphoblastic leukemia (AML, ALL). Here, we test CXCR4-directed theranostics using 68Ga-Pentixafor for PET-imaging and 177Lu/90Y-Pentixather for targeting of CXCR4-expressing leukemic cells and their microenvironment. We found that Pentixafor-PET is feasible in mice and patients and Pentixather effectively reduces leukemic burden in murine models and shows promising first results as salvage therapy before alloSCT in AML patients.
«
CXCR4 is highly expressed in a subset of patients with acute myeloid and lymphoblastic leukemia (AML, ALL). Here, we test CXCR4-directed theranostics using 68Ga-Pentixafor for PET-imaging and 177Lu/90Y-Pentixather for targeting of CXCR4-expressing leukemic cells and their microenvironment. We found that Pentixafor-PET is feasible in mice and patients and Pentixather effectively reduces leukemic burden in murine models and shows promising first results as salvage therapy before alloSCT in AML pat...
»